Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA3 | P07451 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA6 | P23280 | 2/20 | 0.35 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15929964 | 1.00 | LCK (0.50) | LCKCHRM2NFKB1CA12CA1 | |
| SCHEMBL19655070 | 1.00 | LCK (0.50) | LCKCHRM2NFKB1CA12CA1 | |
| SCHEMBL10972803 | 0.97 | LCK (0.48) | LCKCHRM2NFKB1CA12CA1 | |
| SCHEMBL43276 | 0.97 | LCK (0.52) | LCKCHRM2NFKB1CA12CA1 | |
| SCHEMBL176516 | 0.97 | LCK (0.52) | LCKCHRM2NFKB1CA12CA1 | |
| SCHEMBL7166448 | 0.97 | LCK (0.52) | LCKCHRM2NFKB1CA12CA1 | |
| SCHEMBL17123446 | 0.94 | LCK (0.52) | LCKCHRM2NFKB1CA12CA1 | |
| SCHEMBL15591980 | 0.94 | LCK (0.52) | LCKCHRM2NFKB1CA12CA1 | |
| SCHEMBL14790716 | 0.93 | LCK (0.50) | LCKCHRM2NFKB1CA12CA1 | |
| SCHEMBL817857 | 0.93 | LCK (0.50) | LCKCHRM2NFKB1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210187011-A1 | METHOD OF TREATING ACID-BASE DISORDERS | RENIBUS THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210187011-A1 | METHOD OF TREATING ACID-BASE DISORDERS | SLC10A2, SLC10A1, SI | LCK 4187/4885CHRM2 1836/4885NFKB1 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.